World's Best Scientists 2026 revealed!
Ronald M. Bukowski

Ronald M. Bukowski

D-Index & Metrics

Medicine

D-Index
109
Citations
57428
World Ranking
5684
National Ranking
3061

Ronald M. Bukowski publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ronald M. Bukowski sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 598 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ronald M. Bukowski D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald M. Bukowski sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ronald M. Bukowski is affiliated with the Cleveland Clinic in the United States. Their research primarily focuses on medical fields related to cancer, with a strong emphasis on renal cell carcinoma treatment and prostate cancer research.

The main fields of study associated with Ronald M. Bukowski include Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, their work further specializes in subfields such as Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Endocrinology, Diabetes and Metabolism.

Their research topics cover several key areas:

  • Renal cell carcinoma treatment
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Hormonal and reproductive studies

Ronald M. Bukowski has contributed to scientific literature through publications in multiple venues:

  • Journal of Clinical Oncology
  • Clinical Genitourinary Cancer
  • Frontiers in Oncology

Key recent papers authored or co-authored by Bukowski include:

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2023, Journal of Clinical Oncology)
  • Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure (2020, Clinical Genitourinary Cancer)
  • Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer (2020, Frontiers in Oncology)

The scientist has frequently collaborated with several co-authors, including:

  • Robert A. Figlin
  • Robert J. Motzer
  • Thomas E. Hutson
  • Piotr Tomczak
  • M. Dror Michaelson

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Jennifer S. Ko;Arnold H. Zea;Brian I. Rini;Joanna L. Ireland

  • Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

    Tarek M. Mekhail;Rony M. Abou-Jawde;Gabriel BouMerhi;Sareena Malhi

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

    James H. Finke;Brian I Rini;Joanna Ireland;Patricia Rayman

  • Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    Bernard Escudier;Cezary Szczylik;Thomas E. Hutson;Tomasz Demkow

  • Targeted Therapy for Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Ronald M. Bukowski

  • Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

    Olivier Rixe;Ronald M Bukowski;M Dror Michaelson;George Wilding

  • Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

    B. Escudier;C. Szczylik;T. Eisen;W. M. Stadler

  • Loss of T-Cell Receptor ζ Chain and p56lck in T-Cells Infiltrating Human Renal Cell Carcinoma

    James H. Finke;Arnold H. Zea;Jill Stanley;Dan L. Longo

  • Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

    E Van Cutsem;P M Hoff;P Harper;R M Bukowski

  • Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

    Brian I. Rini;Ila Tamaskar;Phillip Shaheen;Renee Salas

  • Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

    Toni K. Choueiri;Anne Plantade;Paul Elson;Sylvie Negrier

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

Frequent Co-Authors

James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Raymond R. Tubbs
Raymond R. Tubbs Cleveland Clinic
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Andrew C. Novick
Andrew C. Novick Cleveland Clinic
Walter M. Stadler
Walter M. Stadler University of Chicago
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Toni K. Choueiri
Toni K. Choueiri Harvard University
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require following the traditional route of medical school. There are many related healthcare pathways available online, each offering flexibility and unique career prospects. For those who are already registered nurses, pursuing one of the cheapest rn to bsn programs can help you advance your credentials while keeping costs manageable.

If you don’t hold a nursing background but want to transition into this rewarding field, you may consider direct entry msn programs for non nurses online. These programs are specifically designed to fast-track your move into nursing and can be completed from anywhere.

Entry into the nursing profession is becoming more accessible too, with online bsn programs for non nurses offering flexible options and less competitive admissions. This is a great choice for career changers who want to start in healthcare.

Those interested in healthcare administration and support roles may look into online medical coding classes with financial aid. This growing field allows graduates to contribute to healthcare operations without direct patient care.

Best Scientists Citing Ronald M. Bukowski

Trending Scientists

Recently Published Articles